Core Viewpoint - Sunshine Nuohuo (688621) announced that it has received the acceptance notice from the National Medical Products Administration for its clinical trial application of the innovative drug ABA001 injection, which is intended for the treatment of hypertension [1]. Company Summary - Sunshine Nuohuo and its wholly-owned subsidiary, Beijing Arna Technology Co., Ltd., have submitted a clinical trial application for ABA001 injection, classified as a Class 1 innovative drug [1]. - The proposed indication for ABA001 injection is hypertension, indicating the company's focus on addressing significant health issues [1].

Group 1: Profit Forecasts - Limin Co. expects a net profit of 465 million to 500 million yuan for 2025, representing a year-on-year increase of 471.55% to 514.57% [1] - Guohui Energy anticipates a net profit of 1.32 billion to 1.47 billion yuan for 2025, reflecting a decline of 50.03% to 55.13% year-on-year [2] - Jiajia Yue forecasts a net profit of 198 million to 228 million yuan for 2025, indicating a growth of 50.06% to 72.79% year-on-year [3] - Xianghe Industry projects a net profit of 120 million to 148 million yuan for 2025, with an expected increase of 59.17% to 96.31% year-on-year [4] - Aojie Technology predicts a net profit of 90 million to 120 million yuan for 2025, showing a growth of 228.34% to 337.79% year-on-year [14] - Shanghai Electric expects a net profit of 1.1 billion to 1.32 billion yuan for 2025, representing an increase of approximately 47% to 76% year-on-year [15] - Tianfu Communication anticipates a net profit of 1.881 billion to 2.15 billion yuan for 2025, reflecting a growth of 40% to 60% year-on-year [16] - Yichang Technology forecasts a net profit of 150 million to 225 million yuan for 2025, indicating a year-on-year increase of 58% to 138% [29] - Shanghai Yizhong expects a net profit of 60 million to 70 million yuan for 2025, representing a significant increase of 760.18% to 903.54% year-on-year [41] Group 2: Loss Forecasts - Kexin Electromechanical anticipates a net profit of 55 million to 70 million yuan for 2025, reflecting a decline of 58.65% to 67.51% year-on-year [11][12] - Kexin Technology expects a net loss of 900 million to 1.2 billion yuan for 2025, which is an increase in loss of 78.67% to 84% year-on-year [10] - Tianyang New Materials forecasts a net loss of 250 million to 180 million yuan for 2025, compared to a loss of 213 million yuan in the previous year [20] - Bo Rui Data anticipates a net loss of 90 million to 100 million yuan for 2025, which is an increase in loss of 15.17 million to 25.17 million yuan year-on-year [19] - Xinlian Integrated expects a net loss of 577 million yuan for 2025, which is a reduction in loss of approximately 40.02% compared to the previous year [40] - Fangshilong forecasts a net loss of 4 million to 6 million yuan for 2025 [30] Group 3: Strategic Developments - Lianlong signed a strategic framework agreement with Runyinglian to enhance the reliability and efficiency of the lubricant additive supply chain in China and the Asia-Pacific region [7] - Han Jian Heshan is planning to acquire a 52.51% stake in Liaoning Xingfu New Materials Co., Ltd., with stock suspension expected for up to 9 trading days [13] - Kai Zhong Precision plans to invest 116 million yuan in a technical transformation and expansion project to meet future capacity demands [34] - Tianfu Communication is expected to engage in clinical trials for its ABA001 injection, which has received approval from the National Medical Products Administration [17]

Core Viewpoint - Sunshine Nuohua (688621.SH) has received the acceptance notice from the National Medical Products Administration for the clinical trial application of its research project ABA001 injection, which aims to treat hypertension [1] Group 1: Product Overview - ABA001 injection is a small interfering RNA (siRNA) drug targeting angiotensinogen (AGT) messenger RNA, utilizing an N-Acetylgalactosamine (GalNAc) delivery system to precisely deliver the drug to liver cells [2] - The drug works by silencing AGT mRNA through the siRNA interference mechanism, effectively blocking the synthesis of AGT protein and inhibiting the Renin-Angiotensin-Aldosterone System (RAAS) that raises blood pressure [2] - Non-clinical studies indicate that a dosage of 1 mg/kg can significantly lower blood pressure, demonstrating good tolerance in animals and high safety, with the potential for long-acting effects allowing administration every three months or six months [2]

Core Viewpoint - Sunshine Nuohe (688621.SH) has received the acceptance notice from the National Medical Products Administration for the clinical trial application of its research project ABA001 injection, which aims to treat hypertension [1] Group 1: Product Overview - ABA001 injection is a small interfering RNA (siRNA) drug targeting angiotensinogen (AGT) messenger RNA (mRNA), utilizing an N-Acetylgalactosamine (GalNAc) delivery system to precisely deliver the drug to liver cells [2] - The drug works by silencing AGT mRNA through the siRNA interference mechanism, thereby blocking the synthesis of AGT protein and fundamentally inhibiting the role of the Renin-Angiotensin-Aldosterone System (RAAS) in raising blood pressure [2] - Non-clinical studies indicate that a dosage of 1 mg/kg can significantly lower blood pressure, with good animal tolerance and high safety, potentially allowing for long-acting effects with administration every 3 to 6 months [2]

Core Viewpoint - Sunshine Nuohe (688621.SH) has received the acceptance notice from the National Medical Products Administration for the clinical trial application of its research project ABA001 injection, which aims to treat hypertension [1]. Group 1: Product Overview - ABA001 injection is a small interfering RNA (siRNA) drug targeting angiotensinogen (AGT) messenger RNA (mRNA), utilizing an N-Acetylgalactosamine (GalNAc) delivery system to precisely deliver the drug to liver cells [2]. - The drug works by silencing AGT mRNA through the siRNA interference mechanism, thereby blocking the synthesis of AGT protein and fundamentally inhibiting the role of the Renin-Angiotensin-Aldosterone System (RAAS) in raising blood pressure [2]. Group 2: Clinical and Non-Clinical Research - Clinical studies of a similar siRNA drug, Zilebesiran, have confirmed the effectiveness and safety of this mechanism, with a single dose showing sustained efficacy for 24 weeks [2]. - Non-clinical studies indicate that a dosage of 1 mg/kg can significantly lower blood pressure, with good tolerance observed in animals, suggesting a high safety profile [2]. - ABA001 injection is expected to offer long-acting blood pressure reduction effects, potentially allowing for administration every three months or six months, thus providing a better treatment option for hypertension patients [2].

Core Viewpoint - Sunshine Nuohuo (688621) has received approval from the National Medical Products Administration for the clinical trial application of its research project ABA001 injection, which is intended for the treatment of hypertension [1]. Company Summary - Sunshine Nuohuo and its wholly-owned subsidiary Beijing Arna Technology Co., Ltd. have been granted a "Notice of Acceptance" for the clinical trial application of ABA001 injection [1]. - The proposed indication for ABA001 injection is hypertension [1].